CURE Pharmaceutical & Therapix Biosciences Signs MOU with Israel’s Assuta Medical Centers to Develop First-in-Class Therape...
July 11 2017 - 8:00AM
CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive
drug delivery technology and pharmaceutical cannabinoid molecule
development company and Therapix Biosciences (Nasdaq:TRPX),
("Therapix"), a specialty clinical-stage pharmaceutical company
dedicated to the development of cannabinoid-based drugs
headquartered in Israel, announced today that they signed a
memorandum of understanding (MOU) to enter into a research
collaboration with Israel’s largest and leading private medical
services centers, Assuta Medical Centers, Ltd., (“Assuta”). The
Companies will collaborate to advance, research, develop and
commercialize potential therapeutic products in the fields of
personalized medicine and cannabinoids.
“As CURE focuses on targeting unmet needs in traditional
pharmaceutical markets that could be disrupted by cannabinoid-based
options, we are continuously looking to help bring new therapeutic
cannabinoid-based products to market and further efforts toward the
creation of personalized medicine,” said Robert Davidson, CEO of
CURE Pharmaceutical. “Our new collaboration with Therapix and
Assuta, two leading companies in Israel, a country that is at the
forefront of cannabinoid-based research in the world, is the
perfect place to start the development of these products.”
Dr. Ascher Shmulewitz, Chairman of Therapix, added, “CURE is the
ideal partner for us to enter this promising field of cutting-edge
personalized cannabinoid-based therapeutics. This deal has all the
signs of a fruitful venture.”
As agreed to in the MOU, the Companies intend to formalize the
pooling of professional, scientific, financial resources and
expertise, in order to benefit from each of its respective
advantages and capabilities to develop new therapeutic products in
the fields of personalized medicine and cannabinoids. Specifically,
CURE and Therapix will provide support and expertise in the
development of pharmaceutical products, while Assuta will support
the early research and development of potential projects through
its research and facilities.
“Assuta is happy to enter into the MOU with CURE and Therapix,
and I am confident that the parties’ cooperation will be a
successful one, with many other projects to follow,” said Professor
Ari Shamiss, CEO of Assuta. “This new collaboration is yet another
step Assuta is taking in the innovation world, and one of many
steps to be taken by Assuta in the field of biopharma.”
About CURE
Pharmaceutical Headquartered in
Oxnard, California, CURE Pharmaceutical (OTCQB:CURR) is a fully
integrated specialty pharmaceutical/bioscience company that
leverages disruptive proprietary drug delivery technologies for a
broad range of molecules serving the biopharmaceutical,
veterinarian, medical foods and pharmaceutical cannabis markets.
CURE develops its patented and proprietary delivery system
(CureFilm™), the most advanced oral thin film on the market today,
from its industry leading full service cGMP manufacturing facility.
The Company’s mission is to deliver proven drugs in a fast and
efficient manner and to improve quality of life. For more
information about CURE Pharmaceutical, please visit its website
at www.curepharmaceutical.com. About Therapix
Biosciences Ltd. Therapix Biosciences Ltd. (Nasdaq:TRPX)
is a specialty clinical-stage pharmaceutical company focused on
developing technologies and therapeutics based on cannabinoid
pharmaceuticals. The Company’s clinical pipeline assets follow a
de-risked 505(b)(2) regulatory pathway benefitting from Therapix’s
unique proprietary formulations based on repurposing an FDA
approved synthetic cannabinoid (dronabinol). Therapix’s lead
compound, THX-TS01, is currently in Phase 2 clinical trials for
Tourette’s Syndrome and the Company intends to initiate a Phase 1
clinical study of THX-ULD01 for the treatment of Mild Cognitive
Impairment, for which no FDA-approved therapies currently exist.
Please visit our website for more information
at www.therapixbio.com.
About Assuta Medical CentersAssuta Medical
Centers (https://www.assuta.co.il/en/) is the largest private
hospital network in Israel, operating 8 hospitals and medical
centers from north to south. Owned by Maccabi Healthcare, the
second largest HMO in Israel, Assuta accounts for about 15% of the
surgeries in Israel and takes care of the health of more than 1
million patients yearly. Assuta holds JCI quality accreditation
with excellence and its service standards are ranked as top tier by
the ministry of health.
Forward-looking statementsThis press release
contains forward-looking statements, which are subject to risks and
uncertainties. All statements, other than statements of fact,
including those statements with respect to the Company's business
development, are forward-looking statements. Forward-looking
statements speak only as of the date made and are not guarantees of
future performance. We undertake no obligation to publicly update
or revise any forward-looking statements.
Public Relations Contact
Andrew Hard
Chief Executive Officer
CMW Media
andrew.hard@cmwmedia.com
P. +1888 829-0070
www.cmwmedia.com
Investor Relations Contact
Shiwei Yin, Grayling
Shiwei.Yin@grayling.com
P. +1646 284-9474
Lucia Domville, Grayling
lucia.domville@grayling.com
P. +1646 284-9416
Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From Apr 2024 to May 2024
Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From May 2023 to May 2024